United States: HRSA Issues 340B Drug Discount Program Civil Money Penalty Proposed Rule

On June 17, 2015, the Health Resources and Services Administration (HRSA) issued a proposed rule to implement civil money penalty (CMP) provisions added to section 340B of the Public Health Service Act1 as part of the Affordable Care Act (ACA).2 Although the proposed rule is relatively limited in scope, and additional 340B program subregulatory guidance is anticipated from HRSA in the future, the proposed rule contains several noteworthy elements that may warrant public comment. HRSA will accept public comments submitted on or before August 17, 2015.


Section 340B of the Public Health Service Act requires manufacturers of covered outpatient drugs to offer discounts to specified classes of "covered entities," which typically include various "safety net" providers serving medically underserved populations. The amount of the discounts is based on manufacturer-supplied pricing data under the Medicaid drug rebate statute, with minimum discounts generally equal to 23.1 percent of a drug's average manufacturer price (AMP) for single-source and innovator multiple-source (i.e., brand) drugs, and 13 percent of AMP for noninnovator multiple-source (i.e., generic) drugs.3 As part of the ACA, Congress amended section 340B to authorize civil money penalties of up to $5,000 for each knowing and intentional "instance of overcharging" a covered entity by a manufacturer.4

The Proposed Rule

The proposed rule addresses three primary issues: (i) the calculation of the 340B "ceiling price" that may be charged to covered entities; (ii) the substantive standards applicable to CMPs; and (iii) the procedures applicable to the imposition of CMPs.

First, proposed section 10.10 of the rule specifies that the "340B ceiling price" is equal to the product of (i) the difference between the AMP for the smallest unit of measure of a product and the Medicaid Unit Rebate Amount, calculated to six decimal places, and (ii) the number of units in the package size in question. HRSA will publish the ceiling price rounded to two decimal places. However, consistent with prior HRSA policies, when the calculated ceiling price is less than $0.01, the ceiling price will be deemed to be $0.01. The proposed rule specifically prohibits manufacturers from using a prior quarter's ceiling price rather than penny pricing. Further, the proposal provides that in the case of a new drug, the manufacturer must estimate the ceiling price for the first three calendar quarters until sufficient Medicaid pricing data is available, and then "true-up" any overcharges to covered entities through rebates or credits by the end of the fourth calendar quarter.5

Second, for the substantive standards for CMP liability, the proposed rule does not address the statutory intent standard requiring "knowing and intentional" overcharges. Instead, the proposed rule focuses primarily on the important mathematical question of what constitutes a discrete "instance of overcharging." Proposed section 10.11(b) defines an instance of overcharging as "any order for a covered outpatient drug, by NDC, which results in a covered entity paying more than the ceiling price." More specifically, each order for an NDC constitutes a single instance, regardless of the number of units ordered. Further, even if an initial charge was correct, if a manufacturer's Medicaid pricing recalculation results in a change to the ceiling price, the failure or documented refusal to provide a credit or refund based on a lower revised ceiling price may also constitute an instance of overcharging. The proposed rule specifies that the manufacturer is obligated to make available 340B discounts regardless of the product's distribution method. On the other hand, the rule also clarifies that an instance of overcharging may only occur if a covered entity identifies a purchase as a 340B order at the time of purchase.

Third, for the CMP process, HRSA has delegated its CMP authority to the HHS Office of Inspector General (OIG), and CMP proceedings will follow the OIG's existing CMP regulations at 42 C.F.R. Parts 1003 (and presumably, Part 1005).

Discussion and Potential Areas for Comment

There are several areas with respect to the calculation of the 340B ceiling price where companies may wish to consider comments, including:

  • Confirming that the $0.01 ceiling price would be multiplied by the package size to determine the package price
  • Clarifying that the use of prior quarter ceiling prices is appropriate where prior quarter Medicaid data may be used (e.g., where there are no sales, or where the calculated AMP is a "false positive")
  • Clarifying whether, in the context of new drug pricing, a manufacturer is only obligated to true-up pricing upon request of a covered entity (as reflected in existing policy), or whether it must do so in all circumstances, and addressing whether the proposed rule allows sufficient time for true-ups

Regarding the definition of an "instance of overcharging," the following issues may warrant comment:

  • The meaning of "knowing and intentional"
  • Specific examples of how the "per NDC order" standard may apply
  • With respect to recalculation-based overcharges, the timeframes that manufacturers have to make corrections, and whether those corrections must be in response to covered entity requests

Finally, manufacturers may wish to seek additional guidance for mechanisms for making 340B prices available for products distributed exclusively through limited specialty channels, and should also consider the potential procedural limits of the OIG's existing CMP regulations (e.g., limitations on discovery mechanisms).


The 340B program is undergoing tremendous change in terms of operational and regulatory oversight. The CMP proposed rule is the first of several upcoming rulemakings in the area, and stakeholders should carefully review these proposals and consider submitting comments where appropriate.


1. 42 U.S.C. 256b.

2. 80 Fed. Reg. 34583 (June 17, 2015).

3. 42 U.S.C. § 1396r-8.

4. Id. § 256b(d)(1)(B)(vi).

5. Again, HRSA states that this approach is consistent with its existing policy. However, its prior guidance suggests that such true-ups are only necessary upon request of a covered entity, rather than an affirmative duty on the part of manufacturers. See 60 Fed. Reg. at 51488 (Oct. 2, 1995).

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions